Ovarian function and reproductive outcomes of female patients with systemic lupus erythematosus and the strategies to preserve their fertility

Obstetrical and Gynecological Survey

Volumn 70, Issue 3, 2015, Pages 196-210

  Oktem, Ozgur ^a,c   Guzel, Yilmaz ^b   Aksoy, Senai ^c   Aydin, Elvin ^c   Urman, Bulent ^a,c  

^a KOÇ UNIVERSITY   (Turkey)

^b ISTANBUL AYDIN UNIVERSITY   (Turkey)

^c AMERICAN HOSPITAL   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; ESTROGEN; GONADORELIN DERIVATIVE; IMMUNOSUPPRESSIVE AGENT;

CRYOPRESERVATION; DRUG CYTOTOXICITY; EMBRYO CRYOPRESERVATION; FEMALE; FERTILITY PRESERVATION; FERTILIZATION IN VITRO; FETUS WASTAGE; HORMONE SUBSTITUTION; HUMAN; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; INTRAUTERINE GROWTH RETARDATION; LUPUS ERYTHEMATOSUS NEPHRITIS; LUPUS VULGARIS; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); NEONATAL LUPUS; NEWBORN DISEASE; OOCYTE CRYOPRESERVATION; OVARIAN TISSUE CRYOPRESERVATION; OVARY DISEASE; OVARY FUNCTION; OVARY INSUFFICIENCY; OVULATION INDUCTION; PREDICTOR VARIABLE; PREECLAMPSIA; PREGNANCY OUTCOME; PSYCHOLOGICAL ASPECT; RANDOMIZED CONTROLLED TRIAL (TOPIC); REPRODUCTION; SHORT SURVEY; SYSTEMIC LUPUS ERYTHEMATOSUS; X CHROMOSOME; CHEMICALLY INDUCED; COMPLICATION; FERTILITY; OVARY; PATHOPHYSIOLOGY; PHYSIOLOGY; PREGNANCY; PREGNANCY COMPLICATION; PRIMARY OVARIAN INSUFFICIENCY;

CYCLOPHOSPHAMIDE; ESTROGENS; FEMALE; FERTILITY; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; OVARY; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY OUTCOME; PRIMARY OVARIAN INSUFFICIENCY;

EID: 84924974317     PISSN: 00297828     EISSN: 15339866     Source Type: Journal    
DOI: 10.1097/OGX.0000000000000160     Document Type: Short Survey

References (102)

1. McMurray RW, May W. Sex hormones and systemic lupus erythematosus: review and meta-analysis. Arthritis Rheum. 2003;48:2100-2110.
2. Cervera R, Khamashta MA, Font J, et al. Morbidity andmortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. Medicine (Baltimore). 2003;82:299-308.
3. Cooper GS, Dooley MA, Treadwell EL, et al. Hormonal, environmental, and infectious risk factors for developing systemic lupus erythematosus. Arthritis Rheum. 1998;41:1714-1724.
4. Lahita RG. The role of sex hormones in systemic lupus erythematosus. Curr Opin Rheumatol. 1999;11:352-356.
5. Costenbader KH, Feskanich D, Stampfer MJ, et al. Reproductive and menopausal factors and risk of systemic lupus erythematosus in women. Arthritis Rheum. 2007;56:1251-1262.
6. Buyon JP, Petri MA, Kim MY, et al. The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: a randomized trial. Ann Intern Med. 2005;142:953-962.
7. Rullo OJ, Tsao BP. Recent insights into the genetic basis of systemic lupus erythematosus. Ann Rheum Dis. 2013;72(suppl 2):ii56-ii61.
8. Scofield RH, Bruner GR, Namjou B, et al. Klinefelter's syndrome (47,XXY) in male systemic lupus erythematosus patients: support for the notion of a gene-dose effect from the X chromosome. Arthritis Rheum. 2008;58:2511-2517.
9. Ballestar E, Esteller M, Richardson BC. The epigenetic face of systemic lupus erythematosus. J Immunol. 2006;176:7143-7147.
10. Lockshin MD. Sex differences in autoimmune disease. Lupus. 2006;15:753-756.
11. Li J, May W, McMurray RW. Pituitary hormones and systemic lupus erythematosus. Arthritis Rheum. 2005;52:3701-3712.
12. Lourenco EV, La Cava A. Cytokines in systemic lupus erythematosus. Curr Mol Med. 2009;9:242-254.
13. Luo CY, Wang L, Sun C, et al. Estrogen enhances the functions of CD4(+)CD25(+)Foxp3(+) regulatory T cells that suppress osteoclast differentiation and bone resorption in vitro. Cell Mol Immunol. 2011;8:50-58.
14. + T cells in the pathogenesis of organ-specific autoimmune diseases. Immunol Today. 1995;16:34-38.
15. + T cell responses: the alternative approaches. Annu Rev Immunol. 1997;15:297-322.
16. Mosmann T. Complexity or coherence? Cytokine secretion by B cells. Nat Immunol. 2000;1:465-466.
17. Harris DP, Haynes L, Sayles PC, et al. Reciprocal regulation of polarized cytokine production by effector B and T cells. Nat Immunol. 2000;1:475-482.
18. Lee TP, Chiang BL. Sex differences in spontaneous versus induced animal models of autoimmunity. Autoimmune Rev. 2012;11:A422-A429.
19. Kim WU, Min SY, Hwang SH, et al. Effect of oestrogen on T cell apoptosis in patients with systemic lupus erythematosus. Clin Exp Immunol. 2010;161:453-458.
20. Perry D, Peck AB, Carcamo WC, et al. The current concept of T (h)17 cells and their expanding role in systemic lupus erythematosus. Arthritis. 2011;2011:810649.
21. H2 cytokines and disease activity in systemic lupus erythematosus. J Rheumatol. 2010;37:2046-2052.
22. Crispin JC, Oukka M, Bayliss G, et al. Expanded double negative T cells in patients with systemic lupus erythematosus produce IL-17 and infiltrate the kidneys. J Immunol. 2008;181:8761-8766.
23. Khan D, Dai R, Karpuzoglu E, et al. Estrogen increases, whereas IL-27 and IFN-gamma decrease, splenocyte IL-17 production in WT mice. Eur J Immunol. 2010;40:2549-2556.
24. Kassi E, Vlachoyiannopoulos PG, Kominakis A, et al. Estrogen receptor alpha gene polymorphism and systemic lupus erythematosus: a possible risk? Lupus. 2005;14:391-398.
25. Lin YJ, Chen RH, Wan L, et al. Association of TNF-alpha gene polymorphisms with systemic lupus erythematosus in Taiwanese patients. Lupus. 2009;18:974-979.
26. Lin YJ, Wan L, Huang CM, et al. IL-10 and TNF-alpha promoter polymorphisms in susceptibility to systemic lupus erythematosus in Taiwan. Clin Exp Rheumatol. 2010;28:318-324.
27. Wang J, Nuite M, McAlindon TE. Association of estrogen and aromatase gene polymorphisms with systemic lupus erythematosus. Lupus. 2010;19:734-740.
28. Peeva E, Zouali M. Spotlight on the role of hormonal factors in the emergence of autoreactive B-lymphocytes. Immunol Lett. 2005;101:123-143.
29. Medeiros PB, Febronio MV, Bonfa E, et al. Menstrual and hormonal alterations in juvenile systemic lupus erythematosus. Lupus. 2009;18:38-43.
30. LaBarbera AR, Miller MM, Ober C, et al. Autoimmune etiology in premature ovarian failure. Am J Reprod Immunol Microbiol. 1988;16:115-122.
31. Blanco-Favela F, Quintal-Alvarez Leanos-Miranda A. Association between prolactin and disease activity in systemic lupus erythematosus. Influence of statistical power. J Rheumatol. 1999;26:55-59.
32. Silva CA, Deen ME, Febronio MV, et al. Hormone profile in juvenile systemic lupus erythematosus with previous or current amenorrhea. Rheumatol Int. 2011;31:1037-1043.
33. Harward LE, Mitchell K, Pieper C, et al. The impact of cyclophosphamide on menstruation and pregnancy in women with rheumatologic disease. Lupus. 2013;22:81-86.
34. Shabanova SS, Ananieva LP, Alekberova ZS, et al. Ovarian function and disease activity in patients with systemic lupus erythematosus. Clin Exp Rheumatol. 2008;26:436-441.
35. Lawrenz B, Henes J, Henes M, et al. Impact of systemic lupus erythematosus on ovarian reserve in premenopausal women: evaluation by using anti-muellerian hormone. Lupus. 2011;20: 1193-1197.
36. Oktem O, Urman B. Understanding follicle growth in vivo. Hum Reprod. 2010;25:2944-2954.
37. Oktay K, Briggs D, Gosden RG. Ontogeny of follicle-stimulating hormone receptor gene expression in isolated human ovarian follicles. J Clin Endocrinol Metab. 1997;82:3748-3751.
38. Visser JA, Themmen AP. Anti-mullerian hormone and folliculogenesis. Mol Cell Endocrinol. 2005;234:81-86.
39. Chemaitilly W, Mertens AC, Mitby P, et al. Acute ovarian failure in the childhood cancer survivor study. J Clin Endocrinol Metab. 2006;91:1723-1728.
40. Plowchalk DR, Mattison DR. Phosphoramide mustard is responsible for the ovarian toxicity of cyclophosphamide. Toxicol Appl Pharmacol. 1991;107:472-481.
41. Oktem O, Oktay K. A novel ovarian xenografting model to characterize the impact of chemotherapy agents on human primordial follicle reserve. Cancer Res. 2007;67:10159-10162.
42. Bines J, Oleske DM, Cobleigh MA. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol. 1996;14:1718-1729.
43. Reh A, Oktem O, Oktay K. Impact of breast cancer chemotherapy on ovarian reserve: a prospective observational analysis by menstrual history and ovarian reserve markers. Fertil Steril. 2008;90:1635-1639.
44. van Rooij IA, Broekmans FJ, te Velde ER, et al. Serum antimullerian hormone levels: a novel measure of ovarian reserve. Hum Reprod. 2002;17:3065-3071.
45. Gruijters MJ, Visser JA, Durlinger AL, et al. Anti-mullerian hormone and its role in ovarian function. Mol Cell Endocrinol. 2003;211:85-90.
46. Ebner T, Sommergruber M, Moser M, et al. Basal level of anti-mullerian hormone is associated with oocyte quality in stimulated cycles. Hum Reprod. 2006;21:2022-2026.
47. Knauff EA, Eijkemans MJ, Lambalk CB, et al. Anti-mullerian hormone, inhibin B, and antral follicle count in young women with ovarian failure. J Clin Endocrinol Metab. 2009;94:786-792.
48. Mok CC, Chan PT, To CH. Anti-mullerian hormone and ovarian reserve in systemic lupus erythematosus. Arthritis Rheum. 2013;65:206-210.
49. Appenzeller S, Blatyta PF, Costallat LT. Ovarian failure in SLE patients using pulse cyclophosphamide: comparison of different regimes. Rheumatol Int. 2008;28:567-571.
50. Mersereau J, Dooley MA. Gonadal failure with cyclophosphamide therapy for lupus nephritis: advances in fertility preservation. Rheum Dis Clin North Am. 2010;36:99-108, viii.
51. Morel N, Bachelot A, Chakhtoura Z, et al. Study of anti-mullerian hormone and its relation to the subsequent probability of pregnancy in 112 patients with systemic lupus erythematosus, exposed or not to cyclophosphamide. J Clin Endocrinol Metab. 2013;98:3785-3792.
52. Gonzalez LA, McGwin G Jr, Duran S, et al. Predictors of premature gonadal failure in patients with systemic lupus erythematosus. Results from LUMINA, a multiethnic US cohort (LUMINA LVIII). Ann Rheum Dis. 2008;67:1170-1173.
53. Liu LL, Jiang Y, Wang LN, et al. Efficacy and safety of my cophenolate mofetil versus cyclophosphamide for induction therapy of lupus nephritis: a meta-analysis of randomized controlled trials. Drugs. 2012;72:1521-1533.
54. Mak A, Cheak AA, Tan JY, et al. Mycophenolate mofetil is as efficacious as, but safer than, cyclophosphamide in the treatment of proliferative lupus nephritis: a meta-analysis and meta-regression. Rheumatology (Oxford). 2009;48:944-952.
55. Henderson LK, Masson P, Craig JC, et al. Induction and maintenance treatment of proliferative lupus nephritis: a meta-analysis of randomized controlled trials. Am J Kidney Dis. 2013;61:74-87.
56. Winzer M, Aringer M. Use of methotrexate in patients with systemic lupus erythematosus and primary Sjogren's syndrome. Clin Exp Rheumatol. 2010;28:S156-S159.
57. Oktem O, Urman B. Options of fertility preservation in female cancer patients. Obstet Gynecol Surv. 2010;65:531-542.
58. de Araujo D, Yamakami L, Aikawa N, et al. Ovarian reserve in adult patients with childhood-onset lupus: a possible deleterious effect of methotrexate? Scand J Rheumatol. 2014;1-9.
59. Ostensen M, Clowse M. Pathogenesis of pregnancy complications in systemic lupus erythematosus. Curr Opin Rheumatol. 2013;25:591-596.
60. Mintz G, Niz J, Gutierrez G, et al. Prospective study of pregnancy in systemic lupus erythematosus. Results of a multidisciplinary approach. J Rheumatol. 1986;13:732-739.
61. Ruiz-Irastorza G, Khamashta MA. Lupus and pregnancy: ten questions and some answers. Lupus. 2008;17:416-420.
62. Andrade R, Sanchez ML, Alarcon GS, et al. Adverse pregnancy outcomes in women with systemic lupus erythematosus from a multiethnic US cohort: LUMINA (LVI) [corrected]. Clin Exp Rheumatol. 2008;26:268-274.
63. Peart E, Clowse ME. Systemic lupus erythematosus and pregnancy outcomes: an update and review of the literature. Curr Opin Rheumatol. 2014;26:118-123.
64. Hayslett JP. Maternal and fetal complications in pregnant women with systemic lupus erythematosus. Am J Kidney Dis. 1991;17:123-126.
65. Bobrie G, Liote F, Houillier P, et al. Pregnancy in lupus nephritis and related disorders. Am J Kidney Dis. 1987;9:339-343.
66. Kong NC. Pregnancy of a lupus patient - a challenge to the nephrologist. Nephrol Dial Transplant. 2006;21:268-272.
67. Fischer-Betz R, Specker C, Brinks R, et al. Low risk of renal flares and negative outcomes in women with lupus nephritis conceiving after switching from mycophenolate mofetil to azathioprine. Rheumatology (Oxford). 2013;52:1070-1076.
68. Lockshin MD. Pregnancy does not cause systemic lupus erythematosus to worsen. Arthritis Rheum. 1989;32:665-670.
69. Nossent HC, Swaak TJ. Systemic lupus erythematosus. VI. Analysis of the interrelationship with pregnancy. J Rheumatol. 1990;17:771-776.
70. Chakravarty EF, Colon I, Langen ES, et al. Factors that predict prematurity and preeclampsia in pregnancies that are complicated by systemic lupus erythematosus. Am J Obstet Gynecol. 2005;192:1897-1904.
71. Buyon JP, Cronstein BN, Morris M, et al. Serum complement values (C3 and C4) to differentiate between systemic lupus activity and pre-eclampsia. Am J Med. 1986;81:194-200.
72. Buyon JP, Tamerius J, Ordorica S, et al. Activation of the alternative complement pathway accompanies disease flares in systemic lupus erythematosus during pregnancy. Arthritis Rheum. 1992;35:55-61.
73. Clowse ME, Magder LS, Witter F, et al. Early risk factors for pregnancy loss in lupus. Obstet Gynecol. 2006;107:293-299.
74. Julkunen H, Jouhikainen T, Kaaja R, et al. Fetal outcome in lupus pregnancy: a retrospective case-control study of 242 pregnancies in 112 patients. Lupus. 1993;2:125-131.
75. Qureshi F, Yang Y, Jaques SM, et al. Anti-DNA antibodies cross-reacting with laminin inhibit trophoblast attachment and migration: implications for recurrent pregnancy loss in SLE patients. Am J Reprod Immunol. 2000;44:136-142.
76. Smyth A, Oliveira GH, Lahr BD, et al. A systematic review and meta-analysis of pregnancy outcomes in patients with systemic lupus erythematosus and lupus nephritis. Clin J Am Soc Nephrol. 2010;5:2060-2068.
77. Unterscheider J, O'Donoghue K, Daly S, et al. Fetal growth restriction and the risk of perinatal mortality-case studies from the multicentre PORTO study. BMC Pregnancy Childbirth. 2014;14:63.
78. Izmirly PM, Kim MY, Llanos C, et al. Evaluation of the risk of anti-SSA/Ro-SSB/La antibody-associated cardiac manifestations of neonatal lupus in fetuses of mothers with systemic lupus erythematosus exposed to hydroxychloroquine. Ann Rheum Dis. 2010;69:1827-1830.
79. Izmirly PM, Costedoat-Chalumeau N, Pisoni CN, et al. Maternal use of hydroxychloroquine is associated with a reduced risk of recurrent anti-SSA/Ro-antibody-associated cardiac manifestations of neonatal lupus. Circulation. 2012;126:76-82.
80. Lee SJ, Schover LR, Partridge AH, et al. American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. J Clin Oncol. 2006;24:2917-2931.
81. Kim SS, Donnez J, Barri P, et al. Recommendations for fertility preservation in patients with lymphoma, leukemia, and breast cancer. J Assist Reprod Genet. 2012;29:465-468.
82. Practice Committees of American Society for Reproductive Society for Assisted Reproductive Technology. Mature oocyte cryopreservation: a guideline. Fertil Steril. 2013;99:37-43.
83. Glujovsky D, Blake D, Farquhar C, et al. Cleavage stage versus blastocyst stage embryo transfer in assisted reproductive technology. Cochrane Database Syst Rev. 2012;7 CD002118.
84. Straub RH. The complex role of estrogens in inflammation. Endocr Rev. 2007;28:521-574.
85. Ostensen M, Brucato A, Carp H, et al. Pregnancy and reproduction in autoimmune rheumatic diseases. Rheumatology (Oxford). 2011;50:657-664.
86. Guballa N, Sammaritano L, Schwartzman S, et al. Ovulation induction and in vitro fertilization in systemic lupus erythematosus and antiphospholipid syndrome. Arthritis Rheum. 2000;43:550-556.
87. Bellver J, Pellicer A. Ovarian stimulation for ovulation induction and in vitro fertilization in patients with systemic lupus erythematosus and antiphospholipid syndrome. Fertil Steril. 2009;92:1803-1810.
88. Cobo A, Diaz C. Clinical application of oocyte vitrification: a systematic review and meta-analysis of randomized controlled trials. Fertil Steril. 2011;96:277-285.
89. Noyes N, Porcu E, Borini A. Over 900 oocyte cryopreservation babies born with no apparent increase in congenital anomalies. Reprod Biomed Online. 2009;18:769-776.
90. Cobo A, Meseguer M, Remohi J, et al. Use of cryo-banked oocytes in an ovum donation programme: a prospective, randomized, controlled, clinical trial. Hum Reprod. 2010;25:2239-2246.
91. Stoop D, Ermini B, Polyzos NP, et al. Reproductive potential of a metaphase II oocyte retrieved after ovarian stimulation: an analysis of 23 354 ICSI cycles. Hum Reprod. 2012; 27:2030-2035.
92. Oktay K, Cil AP, Bang H. Efficiency of oocyte cryopreservation: a meta-analysis. Fertil Steril. 2006;86:70-80.
93. Rienzi L, Cobo A, Paffoni A, et al. Consistent and predictable delivery rates after oocyte vitrification: an observational longitudinal cohort multicentric study. Hum Reprod. 2012;27:1606-1612.
94. Donnez J, Dolmans MM, Demylle D, et al. Livebirth after orthotopic transplantation of cryopreserved ovarian tissue. Lancet. 2004;364:1405-1410.
95. Henes M, Henes JC, Neunhoeffer E, et al. Fertility preservation methods in young women with systemic lupus erythematosus prior to cytotoxic therapy: experiences from the FertiPROTEKT network. Lupus. 2012;21:953-958.
96. del Mastro L, Boni L, Michelotti A, et al. Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with breast cancer: a randomized trial. JAMA. 2011;306:269-276.
97. Gerber B, von Minckwitz G, Stehle H, et al. Effect of luteinizing hormone-releasing hormone agonist on ovarian function after modern adjuvant breast cancer chemotherapy: the GBG 37 ZORO study. J Clin Oncol. 2011;29:2334-2341.
98. Munster PN, Moore AP, Ismail-Khan R, et al. Randomized trial using gonadotropin-releasing hormone agonist triptorelin for the preservation of ovarian function during (neo)adjuvant chemotherapy for breast cancer. J Clin Oncol. 2012;30:533-538.
99. Elgindy EA, El-Haieg DO, Khorshid OM, et al. Gonadatrophin suppression to prevent chemotherapy-induced ovarian damage: a randomized controlled trial. Obstet Gynecol. 2013;121:78-86.
100. Yang B, Shi W, Yang J, et al. Concurrent treatment with gonadotropin-releasing hormone agonists for chemotherapy-induced ovarian damage in premenopausal women with breast cancer: a meta-analysis of randomized controlled trials. Breast. 2013;22:150-157.
101. Gordon C, Isenberg D, Lerstrom K, et al. The substantial burden of systemic lupus erythematosus on the productivity and careers of patients: a European patient-driven online survey. Rheumatology (Oxford). 2013;52:2292-2301.
102. Clowse ME, Chakravarty E, Costenbader KH, et al. Effects of infertility, pregnancy loss, and patient concerns on family size of women with rheumatoid arthritis and systemic lupus erythematosus. Arthritis Care Res (Hoboken). 2012;64:668-674.